CRISPR THERAPEUTICS AG (CRSP) Operating income 2016–2025
CRISPR THERAPEUTICS AG (CRSP) annual operating income history from SEC filings — each fiscal year as reported.
-$664.6MFY2025 · since FY2016: -$68.1M → -$664.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$664.6M | -42.4% |
| FY2024 | -$466.6M | -109.7% |
| FY2023 | -$222.5M | +66.9% |
| FY2022 | -$673.2M | -280.2% |
| FY2021 | $373.5M | +205.4% |
| FY2020 | -$354.4M | -858.3% |
| FY2019 | $46.7M | +129.4% |
| FY2018 | -$158.9M | -145.9% |
| FY2017 | -$64.6M | +5.1% |
| FY2016 | -$68.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CRSP financial trends
CRSP RevenueCRSP Net incomeCRSP Net marginCRSP Gross profitCRSP Gross marginCRSP Operating marginCRSP Operating cash flowCRSP Free cash flowCRSP Capital expendituresCRSP Return on equityCRSP Stock buybacksCRSP Dividends paidCRSP Total assetsCRSP Total liabilitiesCRSP Shareholders’ equityCRSP overview →